""

Hodgkin lymphoma

Recruiting after consultation
Open recruiting

First line therapy

Title: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma: comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD
Phase: III
Contact: Jennifer klemmer / Kontaktperson
Clinical Investigator: Dr. Julia Meissner
Registration: Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe NCT02661503
EudraCT-Number: (siehe EU klinisches Studienregister) 2014-005130-55

Follow-up therapy

Title: A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial With Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR Modified T Cells, MDG1011, in Subjects With High Risk Myeloid and Lymphoid Neoplasms
Phase: I/II
Contact: Diana Six / Study Nurse
Clinical Investigator: Prof. Dr. Michael Schmitt
Registration: Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe NCT03503968
EudraCT-Number: (siehe EU klinisches Studienregister) 2018-000717-20
Title: Abscopal Effect of Radiotherapy and Nivolumab in anti-PD1 Pretreated Relapsed or Refractory classical Hodgkin Lymphoma - An international multicenter Phase II trial
Phase: II
Contact: Jennifer klemmer / Kontaktperson
Clinical Investigator: Dr. Julia Meissner
Registration: Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe NCT03480334
EudraCT-Number: (siehe EU klinisches Studienregister) 2017-003334-82

Surgical Study

There are currently no studies available

Radiotherapy Study

There are currently no studies available

Other study

There are currently no studies available